Farxiga Shortage Update: What Patients Need to Know in 2026

If you've been searching for information about a Farxiga shortage in 2026, here's the most up-to-date information available. The bottom line: Farxiga is not on the FDA's official drug shortage list, and a major milestone occurred in April 2026 that is expected to dramatically improve access to this medication long-term.

Is Farxiga in Shortage in 2026?

No. As of 2026, Farxiga (dapagliflozin) is not on the FDA Drug Shortage database. AstraZeneca has maintained consistent manufacturing output, and the drug is generally available at major pharmacy chains and through mail-order services across the United States.

However, 'no official shortage' does not mean every pharmacy will always have it on the shelf. Localized stock gaps, high local demand, and the transition period following the April 2026 generic launch can still cause individual patients to struggle to fill their prescription on any given day.

The Biggest 2026 Development: FDA Approves First Generic Dapagliflozin

On April 7, 2026, the FDA approved the first generic versions of dapagliflozin tablets — the active ingredient in Farxiga. Multiple manufacturers received simultaneous approval, which means more production capacity than ever before for this medication.

Generic dapagliflozin is bioequivalent to brand-name Farxiga — the same active ingredient, same dose, same clinical effect. This approval covers the same indications as brand-name Farxiga: type 2 diabetes and heart failure hospitalization risk reduction in adults with T2DM and cardiovascular disease or multiple CV risk factors.

Why Might You Still Have Trouble Finding It?

Even without a national shortage, patients report difficulty accessing Farxiga for several reasons in 2026:

Insurance delays: Prior authorization requirements and step therapy policies can delay filling a new or changing prescription by days or weeks.

Cost barriers: At $590–$778 per month retail without insurance, some patients simply can't afford brand Farxiga. Generic competition is expected to lower prices, but this takes time.

Local stock gaps: Pharmacies that don't fill many Farxiga prescriptions may not stock enough to meet a sudden spike in demand.

Generic transition confusion: Some patients are surprised when their pharmacy fills brand Farxiga with the new generic. While legally and clinically equivalent, the sudden switch can cause confusion.

What the Generic Launch Means for Your Wallet

When multiple manufacturers compete to produce the same drug, prices tend to fall — sometimes dramatically. For patients without insurance or with high copays, this is significant news. While it may take several months for prices to settle, generic dapagliflozin is expected to eventually cost a fraction of the brand-name price.

Interestingly, in the early months after generic launch, brand-name Farxiga can sometimes be cheaper than the generic — because AstraZeneca's SavingsRx Card (max $150 savings for cash patients, max $175 for insured patients) can reduce the brand price below some generic cash prices. Always compare both at your specific pharmacy before deciding which to fill.

Farxiga's Expanding Role: Why More Patients Need It Than Ever

One reason filling Farxiga feels harder than it used to is that demand has risen sharply. Farxiga was originally approved for type 2 diabetes in 2014. Over the years, major clinical trials (DAPA-HF, DAPA-CKD, DELIVER) demonstrated its benefits for heart failure and chronic kidney disease — and the drug received additional FDA approvals covering millions more patients.

Today, cardiologists, nephrologists, and endocrinologists all prescribe Farxiga. This broader prescribing base means higher demand across more pharmacy locations, and it can strain stock at pharmacies that previously only needed to fill occasional prescriptions.

What Patients Should Do Right Now

Here are practical steps for patients having trouble filling Farxiga in 2026:

Ask about generic dapagliflozin. It's the same drug and may be easier to find or cheaper at some pharmacies.

Enroll in the Farxiga SavingsRx Card. Eligible commercially insured patients can pay as little as $0 per month (max $175 savings). Visit farxiga.com or call 1-855-332-7944.

Switch to a 90-day mail-order supply. Mail-order pharmacies affiliated with your insurance plan typically carry reliable stock and may offer better pricing for a 90-day fill.

Check multiple pharmacies. Stock varies significantly between locations. medfinder.com can do this on your behalf, calling local pharmacies to find which ones have your medication in stock.

Work with your doctor on prior auth. If insurance is blocking your prescription, your doctor can submit a letter of medical necessity or appeal the denial.

If you've exhausted these options and still can't access Farxiga, speak with your doctor about alternatives like Jardiance or Invokana. Read our full guide to Farxiga alternatives for a detailed comparison.